The BEACON CRC trial demonstrated that BRAF V600E mutations confer resistance to EGFR inhibitors, such as cetuximab, while highlighting the efficacy of combinatorial BRAF/MEK/EGFR inhibition in overcoming this resistance (58). This evidence concerns the gene MAP2K7 and colorectal carcinoma.